| Ticker Symbol: | CRTX |
|---|---|
| Exchange: | NASD |
| Contact Info: | 60 Westview Street Lexington, MA 02421 (781) 402-5700 |
| CEO/President: | Dr. Trevor Phillips, Ph.D. |
| Industry: | Biotechnology / Standard Industry Code: 2834 |
| Description: | A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body\'s inflammatory response. |
| Shares Outstanding: | 42,805 (000) | Market Value: | 16,087 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 27.7% | Number of Inst.Shareholders: | 25 |
| Last Quarter Sales: | 3.3 ($Mil.) | Last Quarter Net Income: | -10.8 ($Mil.) |
| Last Quarter EPS: | -.25 | P/E Ratio: | NE |
| Most Recent Earnings: | Earnings Per Share: | -1.00 | |
| Most Recent Split: | Annual Dividend Rate: | .00 | |
| Most Recent Dividend: | Annual Dividend Yield: | .0% |